International Clinics
Daily
FDA approves pirtobrutinib as first-line treatment for chronic lymphocytic leukemia
On 2 October 2026 the FDA approved Jaypirca (pirtobrutinib) for adults with previously untreated chronic lymphocytic leukemia.